Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma

Robert J. Amato, Randall Millikan, Dania Daliani, Lori Wood, Christopher Logothetis, Alan Pollack

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This prospective Phase II study assesses the clinical efficacy and complications of a treatment regimen of combination chemotherapy with cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Of 46 patients who entered the study between December 1992 and October 1998, 46 were evaluable. Thirty-two achieved a complete remission (70%; 95% confidence interval, 56-83%) after chemotherapy alone. Fourteen achieved a complete remission (30%; 95% confidence interval, 18-46%) after chemotherapy plus consolidation. Forty-three of the 46 patients (93%; 95% confidence interval, 82-97%) remained in remission after a median follow-up period of 27.4 months. No patient experienced nephrotoxic, neurotoxic, or ototoxic effects or hemorrhagic cystitis. No patient had neutropenic fever requiring hospitalization. Thirteen % required platelet transfusions, and 9% required transfusions of packed RBCs. For patients with advanced seminoma, treatment with cyclophosphamide and carboplatin and selective consolidation is safe and effective.

Original languageEnglish
Pages (from-to)72-77
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number1
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Seminoma
Carboplatin
Cyclophosphamide
Confidence Intervals
Consolidation Chemotherapy
Platelet Transfusion
Cystitis
Combination Drug Therapy
Hospitalization
Fever
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amato, R. J., Millikan, R., Daliani, D., Wood, L., Logothetis, C., & Pollack, A. (2000). Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clinical Cancer Research, 6(1), 72-77.

Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. / Amato, Robert J.; Millikan, Randall; Daliani, Dania; Wood, Lori; Logothetis, Christopher; Pollack, Alan.

In: Clinical Cancer Research, Vol. 6, No. 1, 01.01.2000, p. 72-77.

Research output: Contribution to journalArticle

Amato, RJ, Millikan, R, Daliani, D, Wood, L, Logothetis, C & Pollack, A 2000, 'Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma', Clinical Cancer Research, vol. 6, no. 1, pp. 72-77.
Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clinical Cancer Research. 2000 Jan 1;6(1):72-77.
Amato, Robert J. ; Millikan, Randall ; Daliani, Dania ; Wood, Lori ; Logothetis, Christopher ; Pollack, Alan. / Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 1. pp. 72-77.
@article{9e3a6502752944abb1825d86441c367b,
title = "Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma",
abstract = "This prospective Phase II study assesses the clinical efficacy and complications of a treatment regimen of combination chemotherapy with cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Of 46 patients who entered the study between December 1992 and October 1998, 46 were evaluable. Thirty-two achieved a complete remission (70{\%}; 95{\%} confidence interval, 56-83{\%}) after chemotherapy alone. Fourteen achieved a complete remission (30{\%}; 95{\%} confidence interval, 18-46{\%}) after chemotherapy plus consolidation. Forty-three of the 46 patients (93{\%}; 95{\%} confidence interval, 82-97{\%}) remained in remission after a median follow-up period of 27.4 months. No patient experienced nephrotoxic, neurotoxic, or ototoxic effects or hemorrhagic cystitis. No patient had neutropenic fever requiring hospitalization. Thirteen {\%} required platelet transfusions, and 9{\%} required transfusions of packed RBCs. For patients with advanced seminoma, treatment with cyclophosphamide and carboplatin and selective consolidation is safe and effective.",
author = "Amato, {Robert J.} and Randall Millikan and Dania Daliani and Lori Wood and Christopher Logothetis and Alan Pollack",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "72--77",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma

AU - Amato, Robert J.

AU - Millikan, Randall

AU - Daliani, Dania

AU - Wood, Lori

AU - Logothetis, Christopher

AU - Pollack, Alan

PY - 2000/1/1

Y1 - 2000/1/1

N2 - This prospective Phase II study assesses the clinical efficacy and complications of a treatment regimen of combination chemotherapy with cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Of 46 patients who entered the study between December 1992 and October 1998, 46 were evaluable. Thirty-two achieved a complete remission (70%; 95% confidence interval, 56-83%) after chemotherapy alone. Fourteen achieved a complete remission (30%; 95% confidence interval, 18-46%) after chemotherapy plus consolidation. Forty-three of the 46 patients (93%; 95% confidence interval, 82-97%) remained in remission after a median follow-up period of 27.4 months. No patient experienced nephrotoxic, neurotoxic, or ototoxic effects or hemorrhagic cystitis. No patient had neutropenic fever requiring hospitalization. Thirteen % required platelet transfusions, and 9% required transfusions of packed RBCs. For patients with advanced seminoma, treatment with cyclophosphamide and carboplatin and selective consolidation is safe and effective.

AB - This prospective Phase II study assesses the clinical efficacy and complications of a treatment regimen of combination chemotherapy with cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Of 46 patients who entered the study between December 1992 and October 1998, 46 were evaluable. Thirty-two achieved a complete remission (70%; 95% confidence interval, 56-83%) after chemotherapy alone. Fourteen achieved a complete remission (30%; 95% confidence interval, 18-46%) after chemotherapy plus consolidation. Forty-three of the 46 patients (93%; 95% confidence interval, 82-97%) remained in remission after a median follow-up period of 27.4 months. No patient experienced nephrotoxic, neurotoxic, or ototoxic effects or hemorrhagic cystitis. No patient had neutropenic fever requiring hospitalization. Thirteen % required platelet transfusions, and 9% required transfusions of packed RBCs. For patients with advanced seminoma, treatment with cyclophosphamide and carboplatin and selective consolidation is safe and effective.

UR - http://www.scopus.com/inward/record.url?scp=0033980408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033980408&partnerID=8YFLogxK

M3 - Article

C2 - 10656434

AN - SCOPUS:0033980408

VL - 6

SP - 72

EP - 77

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -